Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting
The Breast Journal · 2023
DOI: 10.1155/2023/3614296 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Breast Journal, 2023. Verfasst von Efthymia Skafida und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Therapeutics, Alexandra Hospital, Medical School, Athens, Greece. Hauptthemen laut MEDLINE: Aromatase Inhibitors, Breast Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Third-generation aromatase inhibitors (AIs) are the mainstay of treatment in hormone receptor (HR)-positive breast cancer. Even though it is considered to be a well-tolerated therapy, AI-induced musculoskeletal symptoms are common and may be accused for treatment discontinuation. Recently, selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors changed the therapeutic setting, and currently, ribociclib, palbociclib, and abemaciclib are all approved in combination with nonsteroidal AIs in patients with ER-positive, HER2-negative advanced or metastatic breast cancer. This systematic review aims to identify the frequency of aromatase inhibitor-associated musculoskeletal syndrome (AIMSS) in the adjuvant setting in patients under AI monotherapy compared to patients under combination therapy with AIs and CDK4/6 inhibitors and demonstrate the underlying mechanism of action.
Methods
This study was performed in accordance with PRISMA guidelines. The literature search and data extraction from all randomized clinical trials (RCTs) were done by two independent investigators. Eligible articles were identified by a search of MEDLINE and ClinicalTrial.gov database concerning the period 2000/01/01–2021/05/01.
Results
Arthralgia was reported in 13.2 to 68.7% of patients receiving AIs for early-stage breast cancer, while arthralgia induced by CDK4/6 inhibitors occurred in a much lower rate [20.5–41.2%]. Bone pain (5–28.7% vs. 2.2–17.2%), back pain (2–13.4% vs. 8–11.2%), and arthritis (3.6–33.6% vs. 0.32%) were reported less frequently in patients receiving the combination of CDK4/6 inhibitors with ET.
Conclusions
CDK4/6 inhibitors might have a protective effect against joint inflammation and arthralgia occurrence. Further studies are warranted to investigate arthralgia incidence in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Therapeutics, Alexandra Hospital, Medical School, Athens, Greece.
- Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens School of Medicine, Hippokration General Hospital, Athens, Greece.
- Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece.
ORCID-Profile: Angeliki Andrikopoulou, Evangelos Terpos, Savvina Moustafa, Dimitrios Pectasides, Meletios-Athanasios Dimopoulos, Flora Zagouri, Dimitrios Vassilopoulos
Zitieren
APA
Skafida, E., Andrikopoulou, A., Terpos, E., Markellos, C., Moustafa, S., Pectasides, D., Dimopoulos, M. A., Zagouri, F., & Vassilopoulos, D. (2023). Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting. The Breast Journal. https://doi.org/10.1155/2023/3614296
Vancouver
Skafida E, Andrikopoulou A, Terpos E, Markellos C, Moustafa S, Pectasides D, et al. Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting. The Breast Journal. 2023. doi:10.1155/2023/3614296
BibTeX
@article{Skafida2023,
author = {Skafida, Efthymia and Andrikopoulou, Angeliki and Terpos, Evangelos and Markellos, Christos and Moustafa, Savvina and Pectasides, Dimitrios and Dimopoulos, Meletios-Athanasios and Zagouri, Flora and Vassilopoulos, Dimitrios},
title = {Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting},
journal = {The Breast Journal},
year = {2023},
doi = {10.1155/2023/3614296}
}
EUVIMED